Periodic Reporting for period 1 - RNAging (The role of non coding RNA in organismal ageing)
Periodo di rendicontazione: 2017-03-01 al 2018-08-31
Ageing-associated diseases are a wide spectrum of different pathologies, which share a common molecular cause: the activation of a DNA damage response (DDR) at dysfunctional telomeres.
With this project we aimed to evaluate the effects of telomeric DDR suppression by the use of a novel drug, based on antisense oligonucleotide technology, in a mouse model of premature ageing. The results of these experimental activities provided a prove of concept to apply our novel therapeutic strategy to many ageing-related diseases.
Thanks to robust intellectual property and business development strategy by TTFactor, the project was presented to various investors and eventually an industrial partner was found to foster and support its further development. The partner is a very qualified accelerator, called BiovelocITA, based in Milan and backed by large venture capital firm, discovery funded preclinical work on the candidate molecules with seed funding. The seed phase is due to terminate in February 2019 after which, if successful, a start-up company will be crated to foster further preclinical development.
With this project we aimed to evaluate the effects of telomeric DDR suppression by the use of a novel drug, based on antisense oligonucleotide technology, in a mouse model of premature ageing. The results of these experimental activities provided a prove of concept to apply our novel therapeutic strategy to many ageing-related diseases.
Thanks to robust intellectual property and business development strategy by TTFactor, the project was presented to various investors and eventually an industrial partner was found to foster and support its further development. The partner is a very qualified accelerator, called BiovelocITA, based in Milan and backed by large venture capital firm, discovery funded preclinical work on the candidate molecules with seed funding. The seed phase is due to terminate in February 2019 after which, if successful, a start-up company will be crated to foster further preclinical development.